icon Earnings Announcement After Market Close

Illumina Inc ILMN:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD

Last | 05/01/24 EDT

124.68

+1.63 (+1.32%)

Volume

1,342,693

52 week range

89.00 - 213.91

Open0.00
Day High0.00
Day Low0.00
Prev Close124.68
52 Week High213.91
52 Week High Date05/24/23
52 Week Low89.00
52 Week Low Date11/10/23

Key Stats

Market Cap19.856B
Shares Out159.26M
10 Day Average Volume1.26M
Dividend-
Dividend Yield-
Beta1.20
YTD % Change-10.46

KEY STATS

Open0.00
Day High0.00
Day Low0.00
Prev Close124.68
52 Week High213.91
52 Week High Date05/24/23
52 Week Low89.00
52 Week Low Date11/10/23
Market Cap19.856B
Shares Out159.26M
10 Day Average Volume1.26M
Dividend-
Dividend Yield-
Beta1.20
YTD % Change-10.46

RATIOS/PROFITABILITY

EPS (TTM)-7.34
P/E (TTM)-16.98
Fwd P/E (NTM)145.65
EBITDA (TTM)359.00M
ROE (TTM)-18.79%
Revenue (TTM)4.504B
Gross Margin (TTM)60.95%
Net Margin (TTM)-25.75%
Debt To Equity (MRQ)25.92%

EVENTS

Earnings Date05/02/2024
Ex Div Date-
Div Amount-
Split Date-
Split Factor-

Latest On Illumina Inc

Lightning Round: Illumina is a good company that's poorly run, says Jim CramerApril 29, 2024CNBC.com
Cramer's Lightning Round: Palo Alto Networks is a buyApril 29, 2024CNBC.com
When Tesla shares rise — these 7 stocks have tended to rise too recentlyApril 24, 2024CNBC.com
Jim Cramer goes Mad for March with a special Final Four version of Lightning RoundApril 5, 2024CNBC.com
Cramer's Lightning Round: Uber is a buyApril 5, 2024CNBC.com

Content From Our Affiliates

RBC Capital Reaffirms Their Buy Rating on Illumina (ILMN)April 30, 2024TipRanks
Baird says FDA final LDT rule favorable for Life Sciences, Diagnostics coverageApril 29, 2024TipRanks
Illumina $1B cash outlay for Grail divestment ‘better than fears,’ says EvercoreApril 12, 2024TipRanks
Illumina Gains Approval for GRAIL Divestiture PlansApril 12, 2024TipRanks
Illumina’s planned divestment of GRAIL approved by European CommissionApril 12, 2024TipRanks

Profile

Illumina, Inc. is a provider of sequencing and array-based solutions for genetic and genomic analysis. The Company operates through two segments: Core Illumina and GRAIL. Its Core Illumina segment offers products and services that serve customers in the research, clinical and applied markets, and enable the adoption of a variety of genomic solutions. Its GRAIL segment is a healthcare company focused on early detection of multiple cancers. Its portfolio of integrated...

Stephen Macmillan

Independent Non-Executive Chairman of the Board

Jacob Thaysen

Chief Executive Officer, Director

Ankur Dhingra

Chief Financial Officer

Steve Barnard

Chief Technology Officer

Carissa Rollins

Chief Information Officer

Address

5200 Illumina Way

San Diego, CA

92122-4616

United States

https://www.illumina.com

Top Peers

SYMBOL	LAST	CHG	%CHG
BNTX Biontech SE	89.95	+1.13	+1.27%
CRL Charles River Laboratories International Inc	232.69	+3.69	+1.61%
GMAB Genmab A/S	28.75	+1.06	+3.83%
INCY Incyte Corp	52.94	+0.89	+1.71%
ALNY Alnylam Pharmaceuticals Inc	149.96	+6.01	+4.18%